Lawrence Steinman

Publication Details

  • Statins in the treatment of central nervous system autoimmune disease JOURNAL OF NEUROIMMUNOLOGY Weber, M. S., Youssef, S., Dunn, S. E., Prod'homme, T., Neuhaus, O., Stuve, O., Greenwood, J., Steinman, L., Zamvil, S. S. 2006; 178 (1-2): 140-148

    Abstract:

    Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely prescribed for their cholesterol-lowering properties to reduce atherogenesis and cardiovascular morbidity. Over recent years, statins have also been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. The primary mechanism by which statins alter immune function appears to be mediated through the inhibition of post-translational protein prenylation of small GTP-binding proteins and is largely independent of lipid-lowering. In experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), statins prevent or reverse paralysis and were recently shown to exert synergistic benefit when combined with agents approved for MS therapy. Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials.

    View details for DOI 10.1016/j.jneuroim.2006.06.006

    View details for Web of Science ID 000241251000015

    View details for PubMedID 16860400

Stanford Medicine Resources:

Footer Links: